Retatrutide vs Semaglutide
Both are weekly injections. Both target obesity. But the science, the results, and the mechanism are different. Here is a clean comparison of Retatrutide and Semaglutide for weight loss in Thailand.
Retatrutide
Triple Agonist
Semaglutide
Single Agonist
Retatrutide Wins
- Weight loss: about 24% vs 15%
- Faster visible results
- Triple receptor action
- Greater liver fat reduction
- More complete metabolic effect
Similar Between Both
- Once-weekly injection
- Subcutaneous administration
- Appetite suppression
- GI side effects possible
- Medical guidance recommended
Semaglutide Advantage
- FDA-approved options
- Longer safety history
- More widely known globally
- Oral version available
- More post-market data
How They Work Differently
The mechanism difference explains why the results can be different.
Retatrutide
Triple-hormone agonist
Suppresses appetite, slows gastric emptying, and increases satiety.
Supports insulin response and works together with GLP-1 for appetite control.
Supports fat breakdown, energy expenditure, and liver fat reduction.
Semaglutide
Single-hormone agonist
Suppresses appetite, slows gastric emptying, and increases satiety.
Not targeted by Semaglutide.
Not targeted by Semaglutide.
Full Side-by-Side Comparison
Every major factor, compared clearly.
| Factor | Retatrutide | Semaglutide |
|---|---|---|
| Drug Class | Triple agonist: GLP-1 + GIP + Glucagon | Single agonist: GLP-1 only |
| Average Weight Loss | About 24% of body weight | About 10–15% of body weight |
| Injection Frequency | Once weekly | Once weekly |
| Time to First Results | Often 3–4 weeks | Often 6–12 weeks |
| Liver Fat Reduction | Strong reduction reported in studies | Moderate reduction |
| Metabolic Effect | Broader metabolic action | Mainly appetite and glucose control |
| Fat Burning | Direct glucagon pathway involvement | Mostly indirect through calorie deficit |
| Regulatory Status | Clinical trial / pre-approval stage | Approved branded options available |
| Oral Option | Injection only | Oral option exists |
| Long-Term Data | Less long-term market data | Longer post-market history |
Weight Loss
Retatrutide: About 24% average weight loss.
Semaglutide: About 10–15% average weight loss.
Mechanism
Retatrutide: GLP-1 + GIP + Glucagon.
Semaglutide: GLP-1 only.
Speed
Retatrutide: Results may begin faster.
Semaglutide: Often takes longer to notice.
Approval History
Retatrutide: Newer and still pre-approval.
Semaglutide: Longer approved-use history.
The Weight Loss Results Gap
Visualising what the clinical data actually means for your body.
Starting Weight: 100 kg
Based on average trial results at 48 weeks. Individual results vary.
Starting Weight: 120 kg
Based on average trial results at 48 weeks. Individual results vary.
Starting Weight: 150 kg
Based on average trial results at 48 weeks. Individual results vary.
Which Is Right for You?
An honest guide — not every patient is the same.
Consider Retatrutide if…
You want maximum results and access to the most advanced treatment.
- You have significant weight to lose and want the strongest option.
- You have tried Semaglutide and found results insufficient.
- You have fatty liver concerns or broader metabolic issues.
- You want faster visible progress.
- You want a guided transition from GLP-1 treatment.
Consider Semaglutide if…
Regulatory approval and established track record matter most to you.
- You prefer a medication with longer approved-use history.
- Your target weight loss is moderate.
- You have insurance coverage for branded Semaglutide.
- You want an oral GLP-1 option.
- You are new to GLP-1 therapy.
Already on Semaglutide and want better results?
Many patients compare Retatrutide after plateauing on Semaglutide. Because Retatrutide adds GIP and Glucagon activity, it may offer additional benefit for selected patients. A careful transition plan is recommended.
Side Effects: How They Compare
Both drugs share a similar GI side effect profile — here is what to expect from each.
Shared Side Effects
Because both activate GLP-1, they produce similar gastrointestinal effects, especially early in treatment.
- Mild Nausea (most common, usually weeks 1–3)
- Mild Reduced appetite beyond the intended effect
- Mild Constipation or loose stools
- Mild Injection site irritation
- Mild Fatigue during initial dose adjustment
Retatrutide-Specific Considerations
The glucagon component adds unique considerations not seen with Semaglutide alone.
- Note Slightly elevated heart rate in some patients (glucagon effect)
- Note Greater initial nausea intensity at higher doses
- Note More pronounced appetite suppression
- Benefit Superior liver fat reduction vs Semaglutide
- Benefit Greater metabolic marker improvements
Retatrutide vs Semaglutide FAQ
Important differences, switching guidance, safety considerations, and treatment expectations explained clearly.
Yes. Many people transition from Semaglutide to Retatrutide when weight loss slows, appetite suppression weakens, or metabolic progress plateaus. However, switching should be done carefully because Retatrutide has a broader triple-hormone mechanism involving GLP-1, GIP, and glucagon pathways. Most protocols still begin conservatively with lower starting doses even for previous GLP-1 users.
Clinical trial data suggests Retatrutide may produce greater average weight reduction compared to Semaglutide in many patients. This is believed to result from its triple-receptor activity, which may improve appetite control, energy expenditure, and fat metabolism simultaneously.
Semaglutide mainly targets GLP-1 receptors, while Retatrutide activates GLP-1, GIP, and glucagon receptors together. This additional metabolic activity may help increase calorie expenditure and fat oxidation beyond appetite suppression alone.
Pricing varies depending on dosage, treatment duration, sourcing, and medical supervision. While Retatrutide may cost more in some cases, many people compare overall value based on expected results, appetite control, and long-term effectiveness rather than medication price alone.
Yes. Both Semaglutide and Retatrutide commonly cause gastrointestinal side effects during dose escalation, including nausea, bloating, reflux, constipation, or diarrhea. Proper dose escalation and slower titration are important for improving tolerance.
It depends on the type of side effect experienced previously. Mild nausea may improve with slower escalation, while severe reactions or medical complications require professional evaluation before considering another treatment.
Retatrutide strongly affects glucose regulation and metabolic pathways. People using insulin or diabetes medications should always be monitored carefully because treatment may significantly change blood sugar responses and medication requirements.
Semaglutide currently has a longer regulatory and clinical history. Retatrutide is newer but has generated major attention because of exceptionally strong trial results involving body weight reduction and metabolic improvements in selected patients.
Clinical trial averages suggest Retatrutide may achieve greater overall weight reduction compared to Semaglutide in many individuals. However, actual results vary based on dosage, diet, activity, genetics, adherence, and medical conditions.
Not Sure Which Is Right for You?
Get a clear recommendation based on your health history, weight-loss goal, previous GLP-1 use, side effect concerns, and treatment preference.
- + Suitability review
- + Weight loss goal discussion
- + Side effect comparison guidance
- + Medication comparison guidance
- + Treatment recommendation
Get Free Recommendation
Confirmation within 24 hours · No obligation